Search Results

The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.

157 Results Found

Member

AHA 340B Advocacy Alliance Bulletin - April 22, 2025

AHA 340B Advocacy Alliance Bulletin for April 22, 2025.
Public

The 340B Drug Pricing Program

For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs. Despite significant oversight from HRSA and the program’s proven record of decreasing government spending and expanding access to patient care, some want to scale it back or drastically reduce the benefits that eligible hospitals and their patients receive from the program.
Public

Fact Sheet: 340B Drug Pricing Program Contract Pharmacy Arrangements

Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for patients in vulnerable communities. 
Member

AHA 340B Advocacy Alliance - April 17, 2025

The Administration releases executive order on drug pricing; read AHA’s statement.
Member Non-Fed

TAKE ACTION: Urge Lawmakers to Reject Medicaid Cuts, Protect Access to Care

With your senators and representatives home in their states and districts for the next two weeks, please reach out to your lawmakers and urge them to reject funding cuts to Medicaid and other health care programs as part of reconciliation bill.
Member Non-Fed

Contact Your Lawmakers and Urge Them to Extend Key Health Care Policies Set to Expire Next Month

Please ask your senators and representatives to prevent Medicaid disproportionate share hospital payment cuts from taking effect; extend enhanced low-volume adjustment and Medicare-dependent hospital programs that expand access to care in rural areas; and extend telehealth and hospital-at-home waivers.
Member

AHA 340B Advocacy Alliance Bulletin - March 17, 2025

The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model “was within its statutory authority,” according to a department brief filed with the United States District Court for the District of Columbia.
Member

AHA 340B Advocacy Alliance Bulletin March 13, 2025

AHA 340B Advocacy Alliance Bulletin for March 13, 2025.
Member

340B AHA Advocacy Alliance - March 7, 2025

AHA, others file amicus briefs opposing major drug companies’ 340B rebate models
Member

AHA 340B Advocacy Alliance

The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. District Court for the District of Columbia, urging the court to uphold the Health Resources and Services Administration’s decision to reject Johnson & Johnson’s proposed 340B rebate model in a lawsuit brought by J&J to bar the agency from doing so.